Braveheart Bio (NASDAQ:BRVE) Stock Keeps “Overweight” Rating at Cantor Fitzgerald

by · The Markets Daily

Braveheart Bio (NASDAQ:BRVE – Get Free Report)‘s stock had its “overweight” rating reiterated by equities researchers at Cantor Fitzgerald in a report released on Tuesday, Benzinga reports. They currently have a $40.00 price objective on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 108.22% from the stock’s previous close.

Other analysts have also issued reports about the stock. Jefferies Financial Group began coverage on shares of Braveheart Bio in a report on Monday, August 31st. They issued a “buy” rating and a $48.00 price objective on the stock. Stifel Nicolaus initiated coverage on shares of Braveheart Bio in a research note on Monday, August 31st. They set a “buy” rating and a $45.00 target price for the company. Wall Street Zen upgraded shares of Braveheart Bio to a “hold” rating in a research report on Saturday, August 15th. TD Cowen started coverage on shares of Braveheart Bio in a research note on Monday, August 31st. They issued a “buy” rating on the stock. Finally, The Goldman Sachs Group assumed coverage on shares of Braveheart Bio in a research note on Monday, August 31st. They issued a “buy” rating and a $48.00 price target on the stock. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, Braveheart Bio presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.25.

Get Our Latest Stock Report on BRVE

Braveheart Bio Price Performance

NASDAQ:BRVE opened at $19.21 on Tuesday. Braveheart Bio has a 52 week low of $17.86 and a 52 week high of $32.00. The stock has a market capitalization of $1.73 billion and a P/E ratio of -7.65. The company has a fifty day simple moving average of $24.50.

Braveheart Bio (NASDAQ:BRVE – Get Free Report) last announced its quarterly earnings results on Tuesday, September 8th. The company reported ($2.51) EPS for the quarter, missing the consensus estimate of ($0.25) by ($2.26). Equities analysts expect that Braveheart Bio will post -1.48 EPS for the current year.

Insider Activity

In other Braveheart Bio news, Director David Lubner purchased 55,555 shares of the firm’s stock in a transaction on Friday, August 7th. The stock was bought at an average price of $18.00 per share, with a total value of $999,990.00. Following the transaction, the director directly owned 55,555 shares of the company’s stock, valued at approximately $999,990. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Orbimed Advisors Llc purchased 1,940,000 shares of the company’s stock in a transaction on Friday, August 7th. The stock was acquired at an average price of $18.00 per share, with a total value of $34,920,000.00. Following the purchase, the director owned 11,901,826 shares of the company’s stock, valued at approximately $214,232,868. This represents a 19.47% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought 8,751,942 shares of company stock worth $157,534,956 over the last 90 days.

About Braveheart Bio

(Get Free Report)

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.

Further Reading